Paper51345
Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.
Galbraith RM and 3 others. Lancet, 1975. Cited by 243 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Papers, record 51345. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/51345
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Choriocarcinoma | Major topic |
| Hepatitis B | Major topic |
| Leukemia | Major topic |
| Substance Withdrawal Syndrome | Major topic |
| Adult | |
| Chlorambucil | |
| Cyclophosphamide | |
| Dactinomycin | |
| Female | |
| Hepatitis B Antigens | |
| Humans | |
| Immunosuppression Therapy | |
| Leukemia, Lymphoid | |
| Leukemia, Myeloid | |
| Male | |
| Mercaptopurine | |
| Methotrexate | |
| Prednisolone | |
| Pregnancy | |
| Vincristine |
Source PubMed
Cited by55
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 243 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39,944,583 | Evaluation of hepatitis B virus reactivation prevention measures in immunosuppressed patients: current status and effectiveness. | Transl Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39944583 | PubMed |
| 37,550,198 | [Chinese expert consensus on prevention of hepatitis B virus reactivation after allogeneic hematopoietic stem cell transplantation (2023)]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | https://conductscience.org/library/papers/37550198 | PubMed |
| 34,362,079 | Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. | J Clin Med | 2021 | https://conductscience.org/library/papers/34362079 | PubMed |
| 33,613,534 | Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. | Front Immunol | 2020 | https://conductscience.org/library/papers/33613534 | PubMed |
| 32,483,149 | A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. | Nat Commun | 2020 | https://conductscience.org/library/papers/32483149 | PubMed |
| 32,206,094 | Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. | Ther Adv Musculoskelet Dis | 2020 | https://conductscience.org/library/papers/32206094 | PubMed |
| 31,540,124 | Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. | Viruses | 2019 | https://conductscience.org/library/papers/31540124 | PubMed |
| 31,527,514 | Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. | Viruses | 2019 | https://conductscience.org/library/papers/31527514 | PubMed |
| 29,472,690 | Cisplatin Enhances Hepatitis B Virus Replication and PGC-1α Expression through Endoplasmic Reticulum Stress. | Sci Rep | 2018 | https://conductscience.org/library/papers/29472690 | PubMed |
| 28,834,412 | Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. | Arthritis Care Res (Hoboken) | 2018 | https://conductscience.org/library/papers/28834412 | PubMed |
| 27,329,484 | A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? | Clin J Gastroenterol | 2016 | https://conductscience.org/library/papers/27329484 | PubMed |
| 27,291,888 | Prevention of Hepatitis B reactivation in the setting of immunosuppression. | Clin Mol Hepatol | 2016 | https://conductscience.org/library/papers/27291888 | PubMed |
| 26,943,169 | Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. | J Gastroenterol | 2016 | https://conductscience.org/library/papers/26943169 | PubMed |
| 26,413,224 | Hepatitis B virus reactivation with a rituximab-containing regimen. | World J Hepatol | 2015 | https://conductscience.org/library/papers/26413224 | PubMed |
| 26,192,299 | Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy. | Clin J Gastroenterol | 2009 | https://conductscience.org/library/papers/26192299 | PubMed |
| 25,663,769 | S-phase arrest after vincristine treatment may promote hepatitis B virus replication. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/25663769 | PubMed |
| 25,658,926 | The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. | PLoS One | 2015 | https://conductscience.org/library/papers/25658926 | PubMed |
| 24,303,089 | Hepatitis B virus reactivation with rituximab-containing regimen. | World J Hepatol | 2013 | https://conductscience.org/library/papers/24303089 | PubMed |
| 23,870,415 | Medical virology of hepatitis B: how it began and where we are now. | Virol J | 2013 | https://conductscience.org/library/papers/23870415 | PubMed |
| 23,805,156 | Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis. | Hepat Mon | 2013 | https://conductscience.org/library/papers/23805156 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/51345
GET https://conductscience.org/api/papers/v1/51345/cited_by?page=2